首页> 外文期刊>Pharmacopsychiatry >Clinical Utilization of Pharmacogenetics in Psychiatry – Perspectives of Pharmacists, Genetic Counselors, Implementation Science, Clinicians, and Industry
【24h】

Clinical Utilization of Pharmacogenetics in Psychiatry – Perspectives of Pharmacists, Genetic Counselors, Implementation Science, Clinicians, and Industry

机译:精神病学中药物生物遗传学的临床利用 - 药剂师,遗传辅导员,实施科学,临床医生和行业的观点

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction The use of pharmacogenomic (PGx) testing to guide decisions and improve patient outcomes has increased in recent years. PGx testing represents a decision support tool that may inform dosing, increase the likelihood of treatment response, and identify patients at risk for medication side effects. Methods This is a narrative review of utilization of PGx testing in psychiatry from stakeholders including, pharmacists, genetic counselors, implementation scientists, industry, and clinicians. Results While many limitations exist to streamline use of PGx testing in psychiatry, various stakeholders are crucial to clinical implementation. Discussion PGx testing can assist in medication selection and improve patient outcomes; however, more data are needed to understand when and how to incorporate PGx testing into psychiatric practice.
机译:近年来,介绍药物(PGX)检测使用药物(PGX)测试的使用,提高患者结果增加。 PGX测试代表了一个决策支持工具,可以向剂量通知给药,增加治疗响应的可能性,并鉴定有患有药物副作用风险的患者。 方法这是对利益攸关方的精神病学中PGX测试的利用率的叙述审查,包括药剂师,遗传顾问,实施科学家,行业和临床医生。 结果虽然有许多限制在精神病学中,各种利益相关者对PGX测试的使用是对临床实施至关重要的。 讨论PGX测试可以帮助药物选择并改善患者结果; 但是,需要更多的数据来了解何时以及如何将PGX测试纳入精神审查实践。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号